BioFabUSA / ARMI

Regenerative medicine has long faced a fundamental bottleneck: human tissue engineering remained a largely manual, laboratory-scale process incapable of producing the volumes needed for clinical and commercial viability. BioFabUSA, operating under the Advanced Regenerative Manufacturing Institute (ARMI), set out to solve this by building the world's first automated human tissue manufacturing foundry. The challenge was unprecedented — no established automation framework existed for living biological systems, which require continuous, precise control of temperature, gas exchange, nutrient delivery, and other interdependent parameters that conventional industrial control systems were never designed to manage.

Rockwell Automation provided the integrated automation and control architecture that forms the operational backbone of the BioFabUSA foundry. The system centers on automated bioreactor management, with programmable controllers and process control software maintaining the tightly toleranced biological parameters — pH, dissolved oxygen, temperature, and feed rates — required for consistent tissue production. Rather than adapting off-the-shelf pharmaceutical manufacturing systems, the implementation required purpose-built control logic capable of handling the added complexity of living, responsive biological material. The architecture draws on Rockwell's Allen-Bradley control hardware and FactoryTalk software suite, creating a platform that can be replicated and adapted as the regenerative medicine field scales beyond this initial foundry.

BioFabUSA established the first operational automated human tissue manufacturing foundry in the world — a landmark achievement that shifts regenerative medicine from artisanal lab work toward scalable industrial production. Key outcomes include:

• First-of-kind facility: Demonstrated automated, repeatable control of human tissue manufacturing at a scale previously unachievable
• Platform foundation: Created a replicable automation framework for the broader regenerative medicine industry
• Strategic validation: Secured DARPA funding through ARMI, signaling federal recognition of automated tissue manufacturing as a national defense and healthcare priority

The facility provides proof-of-concept that biological process parameters can be controlled with the consistency pharmaceutical manufacturing demands.

• Biological manufacturing demands control systems that go beyond traditional pharmaceutical automation — living systems introduce feedback dynamics that require adaptive, not just precise, process control.
• First-of-kind facilities carry disproportionate industry value: the frameworks developed at BioFabUSA will inform how the entire regenerative medicine sector approaches scale-up.
• Government funding (DARPA via ARMI) can de-risk automation investments in nascent manufacturing categories where commercial ROI timelines are long.
• Partnering with an established industrial automation vendor accelerates facility deployment and lends regulatory credibility to novel manufacturing processes.
• Proving automated consistency at small scale is the prerequisite for any future commercial expansion — foundry architecture decisions made now will constrain or enable scale later.